Alvotech and Teva get US FDA approval of Selarsdi
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva
US FDA and EMA accepted filings based on the data from OCARINA II, with EU approval anticipated mid-2024 and U.S. approval anticipated September 2024
CHL is strengthening its play in the fast-growing beauty and personal care sector
The demand in Africa for COVID-19 vaccines has declined
The inspection was conducted from April 8 to April 12, 2024 and concluded with no observations
A significant proportion of healthcare professionals still tend to favor branded drugs
The companies also plan to collaborate on several early pipeline projects, further technology exploration, and engineering of scalable manufacturing solutions across Novo Nordisk's portfolio
Empowering Research, Enhancing Proficiency is the theme of this year’s Homoeopathic Symposium
Vericiguat works on a pathway not currently targeted by existing heart failure treatments
The approval marks a significant milestone for the American pharmaceutical company in the field of UC
Subscribe To Our Newsletter & Stay Updated